{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:10:47Z","timestamp":1789017047313,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100484","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:37:38Z","timestamp":1784648258000},"page":"100484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab \u00b1 chemotherapy"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-6855","authenticated-orcid":false,"given":"Diego","family":"Enrico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Wulfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pupareli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Tsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfina","family":"Peralta Tanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Waisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Coradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Revelli Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u00edas","family":"Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Borea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100484_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102693","article-title":"Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN","volume":"93","author":"Zhou","year":"2024","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jlb.2026.100484_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400443","article-title":"Survival of patients with lung adenocarcinoma diagnosed in 2000, 2010, and 2020","volume":"4","author":"Debieuvre","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jlb.2026.100484_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jlb.2026.100484_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.962947","article-title":"Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer","volume":"12","author":"Martin","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jlb.2026.100484_bib5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jlb.2026.100484_bib6","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.jlb.2026.100484_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100484_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11864-019-0653-2","article-title":"The role of circulating tumor DNA in lung cancer: mutational analysis, diagnosis, and surveillance now and into the future","volume":"20","author":"Scilla","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100484_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012454","article-title":"Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and\/or chemotherapy","volume":"13","author":"Andrews","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jlb.2026.100484_bib10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100484_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3518","article-title":"Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +\/- chemotherapy in non-small cell lung cancer (NSCLC)","volume":"38","author":"Ricciuti","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100484_bib12","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1038\/s41467-024-51316-7","article-title":"Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy","volume":"15","author":"Ding","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2026.100484_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jlb.2026.100484_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.hoc.2023.02.005","article-title":"Convergence of precision oncology and liquid biopsy in non-small cell lung cancer","volume":"37","author":"Al-Obeidi","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jlb.2026.100484_bib15","article-title":"Analysis of plasma cell-free DNA by ultra\u2013deep sequencing in patients with stages I to III colorectal cancer","volume":"11","author":"Reinert","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jlb.2026.100484_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100484_bib18","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100484_bib19","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non\u2013small cell lung cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100484_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae344","article-title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"30","author":"Leite da Silva","year":"2025","journal-title":"Oncologist"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:53Z","timestamp":1789014593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"alternative-id":["S2950195426000305"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100484","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab \u00b1 chemotherapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100484"}}